Minor
Suspected
विवरण
Fluconazole inhibits CYP2C8-mediated metabolism of montelukast, modestly increasing montelukast plasma concentrations; the clinical impact is generally minor given montelukast's wide therapeutic index.
तंत्र
Montelukast is primarily metabolised by CYP2C8 and to a lesser extent CYP3A4; fluconazole inhibits both enzymes, reducing montelukast clearance and elevating systemic exposure.
नैदानिक महत्व
Pharmacokinetic modelling predicts a moderate increase in montelukast AUC; no clinical case reports of montelukast toxicity due to fluconazole have been identified.
प्रबंधन
No dose adjustment is required; standard monitoring is adequate.